- Home
- NXE vs IRTC Comparison
NXE vs IRTC Comparison
Compare NXE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXE
- IRTC
- Stock Information
- Founded
- NXE N/A
- IRTC 2006
- Country
- NXE Canada
- IRTC United States
- Employees
- NXE N/A
- IRTC N/A
- Industry
- NXE
- IRTC Medical/Dental Instruments
- Sector
- NXE
- IRTC Health Care
- Exchange
- NXE Nasdaq
- IRTC Nasdaq
- Market Cap
- NXE 4.1B
- IRTC 3.5B
- IPO Year
- NXE N/A
- IRTC 2016
- Fundamental
- Price
- NXE $5.59
- IRTC $119.44
- Analyst Decision
- NXE
- IRTC Strong Buy
- Analyst Count
- NXE 0
- IRTC 10
- Target Price
- NXE N/A
- IRTC $110.40
- AVG Volume (30 Days)
- NXE 8.9M
- IRTC 433.7K
- Earning Date
- NXE 03-06-2025
- IRTC 02-20-2025
- Dividend Yield
- NXE N/A
- IRTC N/A
- EPS Growth
- NXE N/A
- IRTC N/A
- EPS
- NXE 0.20
- IRTC N/A
- Revenue
- NXE N/A
- IRTC $591,839,000.00
- Revenue This Year
- NXE N/A
- IRTC $21.10
- Revenue Next Year
- NXE N/A
- IRTC $16.18
- P/E Ratio
- NXE $29.16
- IRTC N/A
- Revenue Growth
- NXE N/A
- IRTC 20.13
- 52 Week Low
- NXE $4.95
- IRTC $55.92
- 52 Week High
- NXE $8.96
- IRTC $128.52
- Technical
- Relative Strength Index (RSI)
- NXE 32.36
- IRTC 73.66
- Support Level
- NXE $5.82
- IRTC $110.63
- Resistance Level
- NXE $6.74
- IRTC $114.47
- Average True Range (ATR)
- NXE 0.28
- IRTC 4.30
- MACD
- NXE -0.06
- IRTC -0.02
- Stochastic Oscillator
- NXE 2.50
- IRTC 61.70
About NXE Nexgen Energy Ltd.
NexGen Energy Ltd is a mineral exploration company. It is engaged in the acquisition, exploration, evaluation and development of uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin. The Rook I property hosts the world-class Arrow Zone, the Bow discovery. as well as the discovered Harpoon area located northeast of the Arrow deposit.
About IRTC iRhythm Technologies Inc.
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.